References
Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513–522.
Cao, Y., DePinho, R.A., Ernst, M., and Vousden, K. (2011). Cancer research: past, present and future. Nat Rev Cancer 11, 749–754.
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., and He, J. (2016a). Cancer statistics in China, 2015. CA Cancer J Clin 66, 115–132.
Chen, W., Zheng, R., Zeng, H., and Zhang, S. (2014a). Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989–2008. Zhonghua Zhong Liu Za Zhi 36, 796–800.
Chen, S., Zhu, J.H., Wang, F., Huang, S.Y., Xue, W.Q., Cui, Z., He, J., and Jia, W.H. (2015). Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis. Chin J Cancer 34, 2–12.
Chen, W., Zheng, R., Zhang, S., Zeng, H., Xia, C., Zuo, T., Yang, Z., Zou, X., and He, J. (2017a). Cancer incidence and mortality in China, 2013. Cancer Lett 401, 63–71.
Chen, W., Zheng, R., Zhang, S., Zeng, H., Zuo, T., Xia, C., Yang, Z., and He, J. (2017b). Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res 29, 1–10.
Chen, W., Zheng, R., Zhang, S., Zhao, P., Li, G., Wu, L., and He, J. (2013). Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 25, 10–21.
Chen, W., Zheng, R., Zhang, S., Zhao, P., Zeng, H., Zou, X., and He, J. (2014b). Annual report on status of cancer in China, 2010. Chin J Cancer Res 26, 48–58.
Chen, X., Ye, G., Zhang, C., Li, X., and Shen, K. (2016b). Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. Chin J Cancer Res 28, 561–569.
Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27.
Di, S., and Li, Z. (2016). Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Sci China Life Sci 59, 360–369.
Friedl, P., and Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992–1009.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.
Hu, S.Y., Zheng, R., Zhao, F., Zhang, S., Chen, W., and Qiao, Y. (2014). Trend analysis of cervical cancer incidence and mortality rates in Chinese women during 1989–2008. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 36, 119–125.
Ke, T., Fang, W., Hao, B., HongBin, H., WenLing, Z., ZhaoJian, G., Yu, L.X., YaLi, S., and QianJin, L. (2014). Cloning and functional characterization of a novel long non-coding RNA gene associated with hepatocellular carcinoma. Prog Biochem Biophys 41, 153–162.
Li, G., and Chen, W. (2009). Representativeness of population-based cancer registration in China—comparison of urban and rural areas. Asian Pac J Cancer Prev 10, 559–564.
Liao, Q., Zeng, Z., Guo, X., Li, X., Wei, F., Zhang, W., Li, X., Chen, P., Liang, F., Xiang, B., Ma, J., Wu, M., Tang, H., Deng, M., Zeng, X., Tang, K., Xiong, W., and Li, G. (2013). LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene 33, 2098–2109.
Luo, J., Solimini, N.L., and Elledge, S.J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837.
Morris, L.G.T., Sikora, A.G., Tosteson, T.D., and Davies, L. (2013). The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23, 885–891.
Siegel, R.L., Miller, K.D., and Jemal, A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66, 7–30.
Siegel, R.L., Miller, K.D., and Jemal, A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67, 7–30.
Stewart, B., and Wild, C. (2014). World cancer report. Lyon: International Agency for Research on Cancer.
Tang, L.L., Chen, W.Q., Xue, W.Q., He, Y.Q., Zheng, R.S., Zeng, Y.X., and Jia, W.H. (2016). Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett 374, 22–30.
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108.
Varghese, C., and Shin, H.R. (2014). Strengthening cancer control in China. Lancet Oncol 15, 484–485.
Wang, J.B., Jiang, Y., Liang, H., Li, P., Xiao, H.J., Ji, J., Xiang, W., Shi, J.F., Fan, Y.G., Li, L., Wang, D., Deng, S.S., Chen, W.Q., Wei, W.Q., Qiao, Y.L., and Boffetta, P. (2012). Attributable causes of cancer in China. Ann Oncol 23, 2983–2989.
Wang, Y., Chen, T., Lu, L.L., Wang, M., Wang, D., Yao, H., Fan, C., Qi, J., Zhang, Y., and Qu, C. (2017a). Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults. Vaccine 35, 1064–1070.
Wang, Y., Mo, Y., Gong, Z., Yang, X., Yang, M., Zhang, S., Xiong, F., Xiang, B., Zhou, M., Liao, Q., Zhang, W., Li, X., Li, X., Li, Y., Li, G., Zeng, Z., and Xiong, W. (2017b). Circular RNAs in human cancer. Mol Cancer 16, 25.
Wen, C.J., and Chen, S.J. (2016). National research center for translational medicine · Shanghai—national key scientific infrastructure for translational medicine. Sci China Life Sci 59, 1051–1054.
Yang, Y., Liao, Q., Wei, F., Li, X., Zhang, W., Fan, S., Shi, L., Li, X., Gong, Z., Ma, J., Zhou, M., Xiang, J., Peng, S., Xiang, B., Deng, H., Yang, Y., Li, Y., Xiong, W., Zeng, Z., and Li, G. (2013). LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways. PLoS ONE 8, e62869.
Zeng, H., Zheng, R., Guo, Y., Zhang, S., Zou, X., Wang, N., Zhang, L., Tang, J., Chen, J., Wei, K., Huang, S., Wang, J., Yu, L., Zhao, D., Song, G., Chen, J., Shen, Y., Yang, X., Gu, X., Jin, F., Li, Q., Li, Y., Ge, H., Zhu, F., Dong, J., Guo, G., Wu, M., Du, L., Sun, X., He, Y., Coleman, M.P., Baade, P., Chen, W., and Yu, X.Q. (2015). Cancer survival in China, 2003–2005: a population-based study. Int J Cancer 136, 1921–1930.
Zeng, H., Zheng, R., Zhang, S., Zhao, P., He, J., and Chen, W. (2012). Trend analysis of cancer mortality in China between 1989 and 2008. Zhonghua Zhong Liu Za Zhi 34, 525–531.
Zeng, Z.Y., Huang, H.B., Huang, L.L., Sun, M.X., Yan, Q.J., Song, Y.L., Wei, F., Bo, H., Gong, Z.J., Zeng, Y., Li, Q., Zhang, W.L., Li, X.Y., Xiang, B., Li, X.L., Li, Y., Xiong, W., and Li, G.Y. (2014). Regulation network and expression profiles of Epstein-Barr virus-encoded microRNAs and their potential target host genes in nasopharyngeal carcinomas. Sci China Life Sci 57, 315–326.
Zeng, Z.Y., Huang, H.B., Zhang, W.L., Xiang, B., Zhou, M., Zhou, Y.H., Ma, J., Yi, M., Li, X.Y., Li, X.L., Xiong, W., and Li, G.Y. (2011). Nasopharyngeal carcinoma: advances in genomics and molecular genetics. Sci China Life Sci 54, 966–975.
Zhao, P., Dai, M., Chen, W., and Li, N. (2010). Cancer trends in China. Jpn J Clin Oncol 40, 281–285.
Zheng, R., Peng, X., Zeng, H., Zhang, S., Chen, T., Wang, H., and Chen, W. (2015). Incidence, mortality and survival of childhood cancer in China during 2000–2010 period: a population-based study. Cancer Lett 363, 176–180.
Zheng, R., Zeng, H., Zhang, S., Chen, T., and Chen, W. (2016). National estimates of cancer prevalence in China, 2011. Cancer Lett 370, 33–38.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81372907, 81472531, 81472595, 81672683, 81672688, 81772928), the Natural Science Foundation of Hunan Province (2015JJ1022, 2016JC2035) and the Fundamental Research Funds of the Central South University (2014zzts066).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wei, F., Wu, Y., Tang, L. et al. Trend analysis of cancer incidence and mortality in China. Sci. China Life Sci. 60, 1271–1275 (2017). https://doi.org/10.1007/s11427-017-9172-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-017-9172-6